Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report report published on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

RVNC has been the topic of several other research reports. HC Wainwright lowered Revance Therapeutics from a strong-buy rating to a hold rating in a research note on Tuesday, August 13th. Piper Sandler downgraded shares of Revance Therapeutics from a strong-buy rating to a hold rating in a research report on Monday, August 12th. Needham & Company LLC cut shares of Revance Therapeutics from a moderate buy rating to a hold rating in a research report on Tuesday, August 13th. Barclays restated an equal weight rating and issued a $7.00 target price (down from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Finally, William Blair reaffirmed a market perform rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Ten equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Hold and a consensus target price of $10.50.

Revance Therapeutics Price Performance

Shares of Revance Therapeutics stock opened at $5.39 on Monday. The stock has a market cap of $562.98 million, a price-to-earnings ratio of -1.48 and a beta of 1.00. The firm’s 50-day moving average is $5.42 and its two-hundred day moving average is $4.27. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $12.59.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.12. The company had revenue of $65.39 million for the quarter, compared to analysts’ expectations of $66.30 million. During the same quarter in the prior year, the company earned ($0.80) EPS. The firm’s quarterly revenue was up 20.2% on a year-over-year basis.

Institutional Trading of Revance Therapeutics

Large investors have recently made changes to their positions in the business. Victory Capital Management Inc. acquired a new position in Revance Therapeutics during the fourth quarter valued at $93,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Revance Therapeutics by 2.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,364 shares of the biopharmaceutical company’s stock valued at $5,954,000 after buying an additional 13,826 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Revance Therapeutics in the fourth quarter worth about $240,000. Trexquant Investment LP acquired a new stake in Revance Therapeutics during the fourth quarter worth about $578,000. Finally, Quest Partners LLC purchased a new position in Revance Therapeutics during the fourth quarter valued at approximately $84,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.